Migraine Days Drop in Kids Treated With Fremanezumab

According to a study in the New England Journal of Medicine, fremanezumab led to a greater reduction in migraine days per month than placebo in children and adolescents with episodic migraine. Molly O'Brien breaks down the study in this Migraine Minute News Update. Read the study: https://bit.ly/4csROT5 Script: In August of 2025, the FDA approved fremanezumab, sold under brand name Ajovy, for prevention of episodic migraine in kids aged 6 to 17 who meet weight requirements. Now we're getting a look at additional research that supports how effective the drug is. Over the course of three months, 123 young people received a once-per-month injection of fremanezumab, while the other 111 participants got the placebo. According to the study, published in the New England Journal of Medicine, participants who received fremanezumab had fewer migraine days than those in the placebo group. They also had fewer moderate to severe headache days. Nearly half of the group taking the treatment saw at least a 50 percent drop in migraine days… The most common side effect was redness at the injection site. Study authors say a longer follow-up is needed to better understand safety and how well the drug works in kids and teens.